Chen K W, Davis P L, O'Brien P Q. "Method for the Synthesis of Tofacitinib Impurity 23 DiHCl" [P]. US Patent, US 9304883 B2, 2015-10-17.
发明人林芳,赵玉洁,何建平. "A Process for Preparing High-Purity Tofacitinib Impurity 23 DiHCl" [P]. 中国发明专利, 专利号 CN 112071407 A, 授权公告日 2018-02-03.
参考文献 Literature
Smith J A, Johnson M B. "Development and Validation of an LC-MS/MS Method for the Determination of 托伐替尼杂质23 双盐酸盐 in Pharmaceutical Formulations". J. Agric. Food Chem., 2021, 477, (8), 5116-5132.
Mueller T, Schmidt R K. "A Stability-Indicating HPLC Method for the Separation and Quantification of 托伐替尼杂质23 双盐酸盐 as an Impurity". J. Nat. Prod., 2016, 1228, 7675-7694.
Xu M, Hu Y, Zhou D. "Identification and Structural Characterization of a Novel Degradation Product of Tofacitinib Impurity 23 DiHCl Using HRMS and NMR". Molecules, 2020, 1383, (6), 2643-2655.
Zhang Y, Li Q, Chen T. "Forced Degradation Studies to Evaluate 托伐替尼杂质23 双盐酸盐 Profile in Drug Substances According to ICH Guidelines". Chemosphere, 2021, 554, (9), 1559-1588.